Literature DB >> 8473515

Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.

R Donghi1, A Longoni, S Pilotti, P Michieli, G Della Porta, M A Pierotti.   

Abstract

The p53 gene was analyzed in tumor specimens obtained from 52 patients with various types of carcinoma of the thyroid gland by a combined molecular and immunocytochemical approach. The histologic types included 37 well-differentiated papillary and follicular carcinomas, 8 poorly differentiated, and 7 undifferentiated carcinomas. The p53 gene was shown to be unaffected in all differentiated tumors by single-strand conformation polymorphism analysis. However, in two out of eight (25%) of poorly differentiated carcinomas and five out of seven (71%) undifferentiated carcinomas, p53 mutations were identified and subsequently characterized by DNA sequencing. One undifferentiated carcinoma displayed two areas with varying degrees of differentiation. The comparative analysis of the p53 gene, in both the more and the less differentiated area of this tumor, clearly showed that the p53 mutation was confined to the latter component of the tumor specimen. These results indicate that mutations of the p53 gene are associated with the most aggressive histologic types of thyroid tumors, such as the undifferentiated carcinoma and, to a certain extent, the poorly differentiated carcinoma, and that the alterations of this gene represent a late genetic event in human thyroid carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473515      PMCID: PMC288155          DOI: 10.1172/JCI116385

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues.

Authors:  J Gerdes; M H Becker; G Key; G Cattoretti
Journal:  J Pathol       Date:  1992-09       Impact factor: 7.996

2.  Silver enhancement of nickel-diaminobenzidine as applied to single and double immunoperoxidase staining.

Authors:  B Frigo; L Scopsi; C Patriarca; F Rilke
Journal:  Biotech Histochem       Date:  1991       Impact factor: 1.718

3.  Polymorphism at codon 213 within the p53 gene.

Authors:  D Carbone; I Chiba; T Mitsudomi
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

4.  Anaplastic thyroid carcinoma. Immunocytochemical study of 32 cases.

Authors:  N G Ordóñez; A K El-Naggar; R C Hickey; N A Samaan
Journal:  Am J Clin Pathol       Date:  1991-07       Impact factor: 2.493

Review 5.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

6.  Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.

Authors:  P A Wright; N R Lemoine; P E Goretzki; F S Wyllie; J Bond; C Hughes; H D Röher; E D Williams; D Wynford-Thomas
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

7.  p53 mutations in ovarian cancer: a late event?

Authors:  R Mazars; P Pujol; T Maudelonde; P Jeanteur; C Theillet
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

Review 8.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

9.  Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland.

Authors:  T Ito; T Seyama; T Mizuno; N Tsuyama; T Hayashi; Y Hayashi; K Dohi; N Nakamura; M Akiyama
Journal:  Cancer Res       Date:  1992-03-01       Impact factor: 12.701

10.  Clonal expansion of p53 mutant cells is associated with brain tumour progression.

Authors:  D Sidransky; T Mikkelsen; K Schwechheimer; M L Rosenblum; W Cavanee; B Vogelstein
Journal:  Nature       Date:  1992-02-27       Impact factor: 49.962

View more
  94 in total

Review 1.  Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects.

Authors:  N J Sarlis
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

2.  Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas.

Authors:  K M La Perle; S M Jhiang; C C Capen
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  Possible Relation of p53 and mdm-2 Oncoprotein Expression in Thyroid Carcinoma: A Molecular-Pathological and Immunohistochemical Study on Paraffin-Embedded Tissue.

Authors:  Kurt W. Schmid; Agnes Bankfalvi; Swantja Mucke; Dietmar Ofner; Kristina Riehemann; Soren Schroder; Andrea Stucker; Martin Totsch; Barbara Dockhorn-Dworniczak
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

4.  Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.

Authors:  G Bunone; P Vigneri; L Mariani; S Butó; P Collini; S Pilotti; M A Pierotti; I Bongarzone
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 5.  Molecular pathology of thyroid cancer: diagnostic and clinical implications.

Authors:  James A Fagin; Nicholas Mitsiades
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-12       Impact factor: 4.690

Review 6.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

7.  Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.

Authors:  Soeren Latteyer; Vera Tiedje; Katharina König; Saskia Ting; Lukas C Heukamp; Lydia Meder; Kurt Werner Schmid; Dagmar Führer; Lars Christian Moeller
Journal:  Endocrine       Date:  2016-10-01       Impact factor: 3.633

Review 8.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

9.  Poorly differentiated thyroid carcinoma: 5 years after the 2004 WHO classification of endocrine tumours.

Authors:  Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

Review 10.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.